Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00275275
Status:
COMPLETED
Last Update Posted:
2012-08-24
First Post:
2006-01-09
Brief Title:
Pramipexole Conversion to Ropinirole Controlled Release CR
Sponsor:
Rajesh Pahwa MD
Organization:
University of Kansas Medical Center
Study Overview
Official Title:
An Open Label Conversion Study of Pramipexole to Ropinirole Controlled Release CR in Patients With Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A conversion study of Mirapex pramipexole to Requip ropinirole controlled release CR in patients with Parkinsons disease to determine the appropriate conversion ratio and side effects related to the drug
Detailed Description:
Three different arms will be used in this study Each of the three cohorts will be treated sequentially Each participant will be taking Mirapex for PD and will be converted to Requip CR by 1 of 3 conversion factors mgmg 13 14 and 15 from Mirapex to once a day Requip CR The first five subjects of each cohort will have their initial dose administered in the clinic and be monitored for orthostatic changes Assessments of motor function before and after conversion will be done
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None